Verteporfin is a benzoporphyrin derivative and is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.
More Information Supplier PageVerteporfin is a benzoporphyrin derivative and is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.
More Information Supplier PageVerteporfin is a benzoporphyrin derivative and is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.
More Information Supplier PageTamsulosin is an ??1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH).
More Information Supplier PageTamsulosin is an ??1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH).
More Information Supplier PageTamsulosin is an ??1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH).
More Information Supplier PageTamsulosin is an ??1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH).
More Information Supplier PageOmbrabulin is a synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities.
More Information Supplier PageT0901317 is a potent, high affinity liver X receptor (LXR) agonist (EC50 ~ 50 nM, Kd values are 7 and 22 nM for LXR-?? and LXR-?? respectively).
More Information Supplier PageDebio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier Page
